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About 15.4% of human cancers worldwide have been attributed to in-
fections. Among these, blood and liver flukes, notably Schistosoma sp, 
Clonorchis Sinesis, and Opisthorchis Viverrini have been associated with 
the development of various cancer types. Schistosoma sp. promotes col-
orectal cancer (CRC) progression through multiple mechanisms including 
production of toxins, symbiotic action with bacterial agents, and more 
importantly chronic inflammation. Diagnosis of schistosomal colorectal 
cancer (SCC) requires high index of clinical suspicion in endemic areas. 
Novel biomarkers may aid early diagnosis of SCC in patients with chron-
ic intestinal schistosomiasis. Treatment should be tailored to individual 
patients according to the stage and biologic characteristics of the tumour, 
and the extent of hepatosplenic schistosomiasis. Long-term survival after 
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1. Introduction
Colorectal cancer (CRC) is the third most common human cancer. Accounting for approximately 1.8 million new cases and 861,000 deaths in 2018, it 
was considered the second leading cause of cancer death 
worldwide. [1] In addition to genetic factors, several envi-
ronmental influences may interplay in a complex multi-
step process to promote colorectal carcinogenesis. These 
include cigarette smoking, high alcohol consumption, obe-
sity, lifestyles, and oncogenic viral and bacterial agents. [2-4] 
Recently, we highlighted the role of Schistosoma sp., a di-
genetic blood fluke, on the aetiology of colorectal cancer, 
disease progression and the characteristics of patients. [5,6]
Schistosomal colorectal cancer (SCC) has been linked 
to S. japonicum and S. mansoni, the leading causative 
agents of intestinal schistosomiasis, and it has been main-
ly reported in areas of high endemicity of schistosomal 
infection; Southeast Asia, Africa, and the Middle East. [5] 
The disease occurs in younger age group with male to fe-
male ratio being consistently higher than sporadic colorec-
tal cancer. [7-9] Moreover, SCC exhibits more aggressive 
biological behaviour with a larger tumour size at presen-
tation, frequent multifocal and multi-centric distribution, 
and mucinous histology. [7,10-13]
The therapeutic landscape of CRC has evolved signifi-
cantly in recent years. Current and emerging treatment op-
tions include surgical resection, chemoradiation, biologic 
therapy, and immunomodulation.14 Recent research works 
keep insight into predictive and prognostic biomarkers of 
CRC, which may aid diagnosis and the development of 
new treatment strategies. In the current review, we discuss 
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the pathogenesis, diagnosis, and treatment options of SCC 
pointing to novel biomarkers and potential therapeutic tar-
gets in context.
2. Pathogenesis 
The underlying pathogenesis of SCC involves several 
mechanisms, with chronic inflammation seems to play 
a pivotal role (Figure 1). These include production of 
schistosomal toxins notably schistosome worm antigen 
(SWA), soluble egg antigen (SEA), and inducible nitric 
oxide synthase (iNOS), the presence of endogenously pro-
duced carcinogens such as reactive nitrogen and oxygen 
species, down-regulation of immune surveillance, thereby 
favouring tumour progression and conferring a survival 
advantage to Enterobacteriaceae infections, particularly 
Salmonella sp. [6] The latter, in turn, promotes tumorogen-
esis directly through multiple epigenetic mechanisms, or 
indirectly through activation of environmental carcino-
gens. [15-17]
 
Figure 1. Illustration of the possible mechanisms of schis-
tosome-induced colorectal carcinogenesis
3. Molecular Biomarkers
Several molecular changes have been described with 
SCC. Zhang et al. observed a different mutation types in 
the p53 gene, and a marginally significant higher propor-
tion of base-pair substitutions at CpG dinucleotides and 
arginine missense mutations in the p53 gene among S. 
japonicum-associated rectal cancer patients compared to 
those with ordinary rectal cancer. [18] For S. mansoni-as-
sociated CRC, it was shown that schistosomal infection is 
associated with microsatellite instability, which is a sign 
of defective DNA repair. [19,20] This genomic instability 
results in DNA replication errors that preferentially affect 
target genes such as transforming growth factor (TGH)
bRII and insulin-like growth factor (IGF)2R, and render 
them incapable of normal colonocytes homeostasis result-
ing in malignant growth. [21] Madbouly et al. evaluated the 
expression of p53 in patients with SCC, and found that 
mutant p53 overexpression was significantly more fre-
quent in schistosomal than in non-schistosomal colorectal 
cancer. Moreover, p53 overexpression in SCC correlated 
well with nodal metastasis, mucinous carcinoma, and 
tumour multicentricity, thereby serving as a useful prog-
nostic biomarker. [22] Zalata and his associates developed 
a more comprehensive study of the expression pattern of 
p53, Bcl-2, and C-Myc in 75 CRC cases; 24 of these had 
pathological evidence of S. mansoni infection. Although 
they did not find a significant association between parasit-
ism and p53 and C-Myc expression, their results showed 
that SCC are characterized by Bcl-2 overexpression and 
less apoptotic activity than ordinary colorectal tumours. [23]
4. Diagnosis
The clinical presentation of SCC is often non-specific 
with common gastrointestinal symptoms such as altered 
bowel habits and rectal bleeding which could be attributed 
to chronic schistosomiasis or other gastrointestinal dis-
eases. [7,24] Therefore, in non-endemic areas, the diagnosis 
requires high index of clinical suspicion in patients with 
history of schistosomal infection. Recent reports have evi-
denced that S. mansoni-associated CRC is associated with 
significantly higher serum levels of Telomerase, LDH, 
clusterin protein, and CEA when compared to intestinal 
S. mansoni infection only. [25,26] These biomarkers might 
serve as promising tools for early tumour detection in pa-
tients with chronic intestinal schistosomiasis.
Current methods of investigation of SCC involve 
colonoscopy and computed tomographic (CT) scanning, 
whereas histological analysis remains the gold standard 
to confirm the diagnosis. Colonoscopy not uncommonly 
reveals features of concomitant colonic schistosomiasis; 
acute colitis, chronic colitis, or mixed-type colitis, with 
presence of typical yellow nodules in the majority of these 
cases. [7,27] The endoscopic appearance of SCC is hetero-
geneous, but the most prevalent findings are ulcerative 
and fungating masses in the colonic wall, which are not 
uncommonly multi-focal. [7,10,11] Histology frequently re-
veals mucinous adenocarcinomas, with deposited ova in 
the tumour or the adjacent lamina propria (Figure 2). [12,13] 
Enhanced CT scan and virtual CT colonography were 
both shown to be highly valuable tools in the detection, 
characterization, and management of the SACC. The in-
testinal wall appears irregularly thickened in all patients, 
involving a wide range of the intestine. Other common 
CT features include spotty and patchy calcifications with 
obscured margins, tram-track calcifications and soft tissue 
DOI: https://doi.org/10.30564/jor.v1i2.1549
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masses. [10,11]
Figure 2. Photomicrograph showing S. mansoni egg shell 
inside the tumour and dysplastic glands. H&E × 40
5. Treatment and Outcome
5.1 Surgical
Complete mesorectal excision (CME) remains the best 
treatment modality for localized colon cancer that is 
amenable for curative surgical resection (70-80%), and 
provides effective palliation for metastatic disease. [28] For 
rectal cancer, curative surgery options are trans-anal and 
trans-sphincteric local excision, and total mesorectal exci-
sion (TME) with or without sphincter preservation. Lap-
aroscopic-assisted approach is preferred over open col-
orectal resection, and confers better short-term outcomes. 
[29] In a series of 280 patients with SCC, 87 patients had 
laparoscopic resection, and 193 had open surgery. The 
laparoscopic group had earlier postoperative recovery, 
shorter hospital stay, and less surgical morbidities, with no 
increase in intra-operative adverse events. Higher rates of 
schistosomiasis-related complications were noted among 
the open surgery group. It was concluded that laparoscop-
ic treatment is safe and effective for SCC with Child-Pugh 
grade A and B. [30] These results were recently replicated 
in CRC patients with liver cirrhosis caused by various in-
fectious and non-infectious aetiologies. [31]
Generally, patients with SCC have significantly lower 
disease-free and overall survival than those with sporad-
ic CRC. [13,32] These observations could be ascribed to 
the aggressive biological behaviour of SCC and to the 
presence of concomitant hepatosplenic schistosomiasis. 
Furthermore, the pattern of Schistosoma eggs deposition 
correlates well with the overall survival, but it does not 
affect the risk of anastomotic leak, indicating that the 
current standard surgical resection of SCC appears to be 
sufficient. [33] 
 5.2 Non-surgical
Preoperative (neoadjuvant) 5-Fluorouracil (5-FU) based 
chemoradiation or short-course high dose radiation ther-
apy is currently the standard of care for operable T3/4 
or node-positive rectal cancer.34 Following surgery for 
CRC, various regimens of adjuvant treatment are used to 
achieve local control and to prevent systemic tumour dis-
semination, among which combination chemotherapy with 
oxaliplatin has the best curative effect and gives most ben-
efit to patients.35 For metastatic disease, oxaliplatin-based 
(FOLFOX) and irinotecan-based (FOLFIRI) regimens are 
regarded as first-line chemotherapy with comparable effi-
cacy and overall survival. [29] The former regimen is par-
ticularly beneficial in treatment of SCC which frequently 
expresses high levels of clusterin. [26] Nonetheless, as he-
patic perilobular and periportal fibrosis, leading to portal 
blood flow obstruction are frequent pathological findings, 
and active HBV/HCV coinfection is not uncommonly 
seen in patients with schistosomal infection regardless of 
the development of colonic schistosomiasis, [36,37] the use 
of oxaliplatin-based chemotherapy should be cautiously 
considered in SCC patients with portal hypertension, even 
in those with good liver reserve. This is because of the 
risk of hepatotoxicity, sinusoidal obstruction syndrome, 
and subsequent upper gastrointestinal bleeding.  Oxalipla-
tin-based regimen is furthermore associated with a signifi-
cantly increased mortality in portal hypertension patients 
undergoing colorectal cancer surgery. [38,39] Other conven-
tional (NON-OXALI) chemotherapeutic regimens can be 
acceptable alternatives in those patients. 
In the last decade, novel biologic therapies, targeting 
either epidermal growth factor signalling or angiogenesis, 
have been used in combination with cytotoxic agents as 
standard regimens for metastatic and advanced CRC. In-
hibitors of the vascular endothelial growth factor (VEGF), 
an angiogenic molecule expressed in many patients with 
CRC and preferentially over-expressed on SCC cells, 
[11] among others, were shown to improve the progres-
sion-free and overall survival in advanced CRC with vari-
able efficacy depending on the concurrent chemotherapy 
regimen utilized. [29] More recently, immunotherapy has 
emerged as a promising therapeutic option that selectively 
targets cancer-dependent pathways and avoids chemother-
apy-related toxicities, thereby improves patient tolerance. 
This modality comprises immune checkpoints modula-
tion, adoptive cell transfer, cancer vaccines, and oncolytic 
viral therapy. Nevertheless, the immunomodulating agents 
that have been investigated so far showed either mini-
mal efficacy or have not yet proceeded on to later phase 
studies. [40] The clinical response rate to immunothera-
DOI: https://doi.org/10.30564/jor.v1i2.1549
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py and progression-free survival could be significantly 
ameliorated by targeting certain subsets of CRC such as 
mismatch repair-deficient (MMR-d) and microsatellite in-
stability-high (MSI-H) metastatic tumours, which account 
for approximately 15% of all CRC and 42% of SCC. [40,41] 
Additionally, modulating MDSC- and Treg-mediated im-
munosuppression may be a beneficial strategy to improve 
the efficiency of immunotherapeutic interventions, partic-
ularly in SCC cases. [42,43] 
6. Conclusion
Although the carcinogenesis induced by Schistosoma sp. 
has been actively investigated, the causal relationship 
between the parasite and CRC is still poorly understood. 
The molecular biology of SCC must be further studied. 
Identification of predictive and prognostic biomarkers at 
an early stage is of paramount importance if the long-term 
outcome of surgery is to be improved. Further studies are 
warranted to explore new treatment strategies for SCC, 
and more effective means of controlling schistosomiasis 
in endemic areas. 
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